ClinicalTrials.gg
RecruitingNCT07299409Updated Oct 6, 2026

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

A Phase 2 interventional study of Sacituzumab Govitecan (SG) in Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic and Breast Cancer, sponsored by Nathalie Levasseur. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Nathalie Levasseur · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms — 11 open to participants now, 18 under way, 6 of them phase 3. sacituzumab govitecan · Triple Negative Breast Neoplasms.

Planned enrollment
20th of 21
24 · median 138
Started
2026
with 1 other
Phase 2
10 of 21
7 open now
Primary completion
2027-08
later than 10 of 17 live
Registered
18th of 21
by date
Lead sponsor
1 of 21
Nathalie Levasseur

Among the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, this one is the 20th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 18th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received prior treatments in the advanced setting. It will also look at whether the effectiveness of the drug differs between TNBC adults with homologous recombination deficiency (HRD) subtypes and those with non-HRD subtypes. The main questions this study aims to answer are:

  • Will patients with advanced TNBC who haven't received prior treatment in the advanced setting respond better (i.e., slowed disease progression) when given SG as a first-line treatment?
  • Does the overall response rate of SG differ between HRD vs non-HRD advanced TNBC patients without prior treatment in the advanced setting?

Participants will:

  • Be given drug SG on days 1 and 8 of 21-day cycle(s)
  • Will continue (repeat) 21-day cycles until disease progression or voluntary withdrawal
  • Visit the clinic for treatments on days 1 and 8
  • Have long-term follow-up every 12 weeks via phone or in-clinic
Read the detailed description

This study is a non-randomized phase II single-arm trial of first-line sacituzumab govitecan (SG) in participants with advanced triple-negative breast cancer who have not received prior treatment in the advanced setting. It is designed to assess the overall response rate (ORR) of SG as well as compare the ORR of SG between homologous recombination-deficient (HRD) vs non-HRD in advanced TNBC patients, stratified by molecular subtypes using whole-genome and transcriptome analysis (WGTA). The 21-day cycle(s) treatment duration allows us to gather the necessary data to meet our primary and secondary objectives and exploratory endpoints. This study will be conducted in compliance with the protocol, the International Council of Harmonisation Good Clinical Practice guidelines, and every applicable regulatory requirement(s). This includes permitting study-related monitoring, audits, research ethics board review, and regulatory inspections, providing direct access to source data and documents.

03

Conditions studied

  • Advanced Triple Negative Breast Cancer
  • Breast Cancer Metastatic
  • Breast Cancer

Browse trials for

Keywords

  • advanced breast cancer
  • Sacituzumab govitecan
  • genomics
  • whole-genome and transcriptome analysis
  • triple negative breast cancer
  • Personalized OncoGenomics (POG)
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 24 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with Nathalie Levasseur as lead sponsor.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following criteria to be eligible for participation in this study:

  1. Willing and able to provide .
  2. Age >18 years old at the time of informed consent and has signed informed consent before any trial related activities are conducted according to local guidelines.
  3. For participants of (menstruation within \<2 years): negative serum pregnancy test within 14-days prior to enrollment and must be willing to use Health Canada-approved effective methods (e.g., hormonal contraceptives, intrauterine device or system, tubal ligation, or double barrier method) starting 1 week prior to study treatment, throughout the study, and for 6 months following the last dose of SG.
  4. For participants considered not of child-bearing potential (): must meet one of the following criteria at the time of study entry:

    i. Prior bilateral oophorectomy ii. Age > 60 iii. Age \< 60 with >12 months of spontaneous amenorrhea (not due to chemotherapy, tamoxifen, toremifene, or ovarian suppression) and laboratory confirmation of postmenopausal FSH and estradiol levels per local postmenopausal reference ranges iv. Ovarian suppression with gonadotropin-releasing hormone (GnRH) agonist (e.g., goserelin) initiated >28 days before Cycle 1 Day 1

  5. Advanced (locoregionally recurrent and non-operable, or ) triple-negative breast cancer patients not amenable to curative therapy (surgery and/or radiotherapy), including those who are PDL1 negative (combined positive score [cps] \<10), immuno-oncology therapy ineligible, or who had early-relapse after therapy and not eligible for immuno-oncology in the setting.
  6. and/or cytologically confirmed diagnosis of estrogen-receptor negative breast cancer by local laboratory testing (based on most recently analyzed ).
  7. -negative breast cancer (based on most recently analyzed biopsy) defined as negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, SISH) test is required by local laboratory testing, as defined in the relevant American Society of Clinical Oncology / College of American Pathologists Guidelines.
  8. Not previously received systemic therapy in the advanced setting.
  9. Participants can have measurable or non- by CT or MRI as per Version 1.1 criteria as evaluated locally. Tumour lesions situated in a previously irradiated area are considered measurable if unequivocal progression has been documented in such lesions since radiation. All radiology studies must be performed within 28-days of Day 1 Cycle 1.
  10. (ECOG) performance status 0-1.
  11. > 3 months.
  12. Acceptable bone marrow and organ function defined by the following laboratory values without transfusion or growth factor support within 2 weeks of treatment initiation:

    a. > 1.0 x 109/L i. > 100 x 109/L ii. > 90 g/dL iii. Potassium, sodium, calcium (corrected for serum albumin), and magnesium within normal limits.

    iv. \< 1.5 v. Serum creatinine \<1.5 x (ULN) or calculated (Cockroft-Gault) or measured ≥50 mL/min/1.73 m2 b. In absence of liver metastases, and AST should be below \<3.0 x ULN. If the participant has liver metastases, ALT and AST should be \< 5.0 x ULN.

    c. In absence of liver metastases, total serum \< ULN; If the participant has liver metastases, total bilirubin \< 3.0 x ULN with direct bilirubin \< 1.5 x ULN.

  13. Consents to allow access and provision of pre- and post-treatment biopsy specimens for study purposes.
  14. Able to communicate with the Investigator and comply with the requirements of the study procedures.
  15. Controlled (as per clinical determination) is allowed in the study at least 4 weeks before treatment. Controlled brain metastasis is defined as asymptomatic brain metastasis or no longer requiring high doses of (>10 mg Dexamethasone per day) for central nervous system (CNS) symptom management. Anticonvulsants and stable corticosteroids dose can be included in the study.

Waivers to the inclusion criteria will NOT be allowed.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Are within 4 weeks of participating in any other type of medical research judged by the Investigator to not be scientifically or medically compatible with this study.
  2. Tumour not accessible or not safe to perform .
  3. Has a known to SG, irinotecan or its active metabolite SN-38.
  4. Has received prior antibody-drug conjugate containing a topoisomerase 1 inhibitor.
  5. Has a history of significant cardiovascular diseases, such as congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction, serious cardiac arrhythmia, (ECG) findings or any other clinically significant cardiovascular condition, as determined by the Investigator.
  6. Has a history or evidence of any condition or laboratory abnormality that would place the participant at undue risk, as determined by the Investigator.
  7. Currently active virus (HBV) or active virus (HCV).

    1. For participants with a history of HBV infection, a hepatitis B core antibody test should be conducted at screening. If positive, hepatitis B DNA testing will be performed and if active HBV infection is ruled out, the participant may be eligible.
    2. Those who are HCV antibody positive with undetectable HCV viral load may be eligible.
  8. Has an active (HIV) infection (e.g., with detectable viral load).

    a. Participants positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.

  9. Has not had resolution of all acute toxic effects of prior anti-cancer therapy to version 5.0 grade \<1 (except toxicities not considered a safety risk for the participant at Investigator's discretion, e.g. grade 2 peripheral neuropathy from prior chemotherapy).
  10. Have an active second . Participants with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or participants with surgically cured tumours with low risk of recurrence (e.g., non-melanoma skin cancer, confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.
  11. Have known, untreated, active central nervous system (CNS) . Participants with previously treated may participate provided they have stable CNS disease, defined as no longer symptomatic from brain metastasis or no longer requires higher doses of (>10mg Dexamethasone per day) for CNS symptom management. Anticonvulsants and stable corticosteroids dose can be included in the study. Screening for brain metastasis is not required for enrollment.
  12. Pregnancy or breast feeding.
  13. Has inadequate hematologic, renal and hepatic function as outlined above in inclusion criteria.
  14. Has a pre-existing condition with uncontrolled diarrhea, chronic inflammatory bowel disease (Ulcerative colitis, Crohn's Disease), or gastrointestinal perforation within 6-months prior to enrollment.
  15. Has active serious infection requiring antibiotics.
  16. Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may confound study interpretation or prevent completion of study procedures and follow-up examinations.
  17. Received a within 30 days prior to enrollment.
  18. Current and/or prior use of systemic anticancer therapies, aside from the study drug. High-dose systemic corticosteroids (>20mg of prednisone or its equivalent) is not allowed within 2 weeks of Cycle 1 Day 1. Premedication with corticosteroids or the use of corticosteroids for treatment-related adverse events are permitted.
  19. Persons of (i.e., menstruation within \< 2 years) who are unable or unwilling to use Health Canada approved highly effective methods of (hormonal contraceptives, intrauterine device or system, vasectomy, tubal ligation, or double-barrier method), or abstinence during the treatment period and for 6 months following last dose of study drug.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Sacituzumab Govitecan

    Patients will receive SG at an initial dose of 10 mg per kilogram intravenously on day 1 and 8 of 21-day cycles. Treatment and cycles will continue until there is evidence of disease progression, significant toxicity, or if the participant or Investigator decide to discontinue treatment for any reason.

    Drug: Sacituzumab Govitecan (SG)

Interventions

  • DrugSacituzumab govitecanStudies of Sacituzumab govitecanSacituzumab govitecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.

    Also known as: Trodelvy

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) of SG in advanced TNBC

    To evaluate the overall response rate (ORR) of Sacituzumab govitecan (SG) in advanced triple-negative breast cancer (TNBC) patients without prior treatment in the advance setting, stratified by molecular subtypes using whole-genome and transcriptome analysis (WGTA).

    Time frame: Up to an average of 6 months

  2. ORR of SG between HRD vs non-HRD in advanced TNBC

    2\. To compare the ORR of SG between homologous recombination-deficient (HRD) vs non-HRD advanced TNBC patients without prior treatment in the advance setting, utilizing WGTA.

    Time frame: Up to an average of 6 months

Secondary outcomes

  1. Evaluate clinical benefit rate (CBR) of SG in advanced TNBC

    To evaluate the clinical benefit rate (CBR) of SG in advanced TNBC, stratified by molecular subtypes identified through WGTA.

    Time frame: Up to an average of 6 months

  2. Assess progression-free survival (PFS) and overall-survival (OS) in advanced TNBC treated with SG

    To assess progression-free survival (PFS) and overall survival (OS) in advanced TNBC patients receiving SG, stratified by molecular subtypes using WGTA.

    Time frame: Up to an average of 12 months

  3. Number of advanced TNBC participants receiving SG in first-line setting with treatment-related adverse events as assessed by CTCAE v5.0

    To assess the safety and toxicity profile in advanced TNBC participants receiving SG in the first-line setting per the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for grade 2-4 toxicities.

    Time frame: Up to an average of 3 months

  4. Changes in health-related quality of life when treated with SG

    To assess changes in health-related quality of life using EORTC QLQ-CL30 version 3.0 questionnaire in advanced TNBC patients undergoing treatment with SG.

    Time frame: At follow-up, within 30 days following the last dose of study drug

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18. PubMed 31208270 ↗
  • Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs Today (Barc). 2019 Sep;55(9):575-585. doi: 10.1358/dot.2019.55.9.3039669. PubMed 31584574 ↗
  • Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortes J, O'Shaughnessy J, Dieras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PubMed 33882206 ↗
  • Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984. PubMed 33198517 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 19 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Jan 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Dec 23, 2025
StartActual
Jan 20, 2026was Dec 2025
Primary completionEst.
Aug 2027
CompletionEst.
Mar 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
BC Cancer - Vancouver Center is now Recruiting
Oct 6, 2026
Start date
Dec 2025→Jan 20, 2026 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    BC Cancer - Vancouver Center is now Recruiting
    Start date Dec 2025→Jan 20, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07299409
Lead sponsor
Nathalie Levasseur
Responsible party
Nathalie Levasseur (Medical Oncologist, Principal Investigator, British Columbia Cancer Agency) — Sponsor-investigator
First posted
Dec 23, 2025
Start date
Jan 20, 2026
Primary completion
Aug 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Dr. Nathalie LeVasseur, MD
Contact
nathalie.levasseur@bccancer.bc.ca
604-877-6000 ext. 672207

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion